Summary

Combination chemotherapy requires compromises in drug dosage and treatment intervals because of acute and cumulative toxicities. The sequential use of monotherapies, however, allows for the use of high doses of single agents and dose-dense treatment intervals, and such regimens have been very effective in cases of early breast cancer with high risk of recurrence. This article discusses data from the first interim safety analysis of the Study of Nab-Paclitaxel in High-Risk Early Breast Cancer [GAIN2; NCT01690702], demonstrating acceptable initial toxicity profiles.